LCPE:LSE:LSE-Ossiam Shiller Barclays Cape Europe Sector Value TR UCITS (GBX)

ETF | Others |

Last Closing

USD 44330

Change

+60.00 (+0.14)%

Market Cap

USD 0.17B

Volume

6.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

N/A

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 584.80B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 583.82B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

N/A

USD 204.07B
0QZ3:LSE Qualcomm Inc.

N/A

USD 202.26B

ETFs Containing LCPE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.91% 40% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.91% 37% F 45% F
Trailing 12 Months  
Capital Gain 9.68% 43% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.68% 40% F 48% F
Trailing 5 Years  
Capital Gain 47.14% 66% D+ 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.14% 65% D 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 10.59% 69% C- 71% C-
Dividend Return 10.59% 68% D+ 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.89% 66% D+ 80% B-
Risk Adjusted Return 107.13% 97% N/A 98% N/A
Market Capitalization 0.17B 58% F 33% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike